Traditional Chinese medicine(TCM)is a valuable resource for the Chinese nation.With its rich theoretical foundation and long-term practical experience,it provides a solid foundation and rich source for various types o...Traditional Chinese medicine(TCM)is a valuable resource for the Chinese nation.With its rich theoretical foundation and long-term practical experience,it provides a solid foundation and rich source for various types of pharmaceutical innovation.The European Union(EU)established Committee on Herbal Medicinal Products(HMPC)and issued 2004/24/EC Directive and 2001/83/EC Directive,which provides legal protection for strengthening the management of traditional medicines and unifying the drug registration standards of member states.It also provides the possibility for Chinese herbal medicine,a precious medical resource,to enter the European market and benefit European citizens.However,in the application process by Chinese traditional medicine manufacturers,there are practical problems such as unclear mechanism of action and differences in drug quality requirements between China and EU.By selecting an appropriate application direction and strategy,the type of drug applied is inclined to the direction of simpler drugs with a simpler mechanism of action.Meanwhile,the policy advantages of local drug manufacturers should be fully taken to strengthen bilateral or multilateral cooperation and other ways to deal with it,providing the possibility to promote the traditional Chinese herbal medicine to go abroad,better serve the people of all countries,and promote the international development of TCM.展开更多
基金The First Batch of the"13th Five-Year Plan"Key Field Special Project of China Academy of Chinese Medical Sciences"Research on the History of Medical Exchanges between China and the Nine Countries along the Belt and Road"(Part 4)-Research on the History of Chinese-Western Exchanges in Chinese Materia Medica"(zz10-011-1-4)The 13th Batch of Self-Selected Topics by China Academy of Chinese Medical Sciences"Collation and Research of Historical Materials on Sino-Western Exchanges in Traditional Material Medica(Late Ming and Early Qing-2017)"(zz130505)。
文摘Traditional Chinese medicine(TCM)is a valuable resource for the Chinese nation.With its rich theoretical foundation and long-term practical experience,it provides a solid foundation and rich source for various types of pharmaceutical innovation.The European Union(EU)established Committee on Herbal Medicinal Products(HMPC)and issued 2004/24/EC Directive and 2001/83/EC Directive,which provides legal protection for strengthening the management of traditional medicines and unifying the drug registration standards of member states.It also provides the possibility for Chinese herbal medicine,a precious medical resource,to enter the European market and benefit European citizens.However,in the application process by Chinese traditional medicine manufacturers,there are practical problems such as unclear mechanism of action and differences in drug quality requirements between China and EU.By selecting an appropriate application direction and strategy,the type of drug applied is inclined to the direction of simpler drugs with a simpler mechanism of action.Meanwhile,the policy advantages of local drug manufacturers should be fully taken to strengthen bilateral or multilateral cooperation and other ways to deal with it,providing the possibility to promote the traditional Chinese herbal medicine to go abroad,better serve the people of all countries,and promote the international development of TCM.
